Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vericel Corp    VCEL

VERICEL CORP

(VCEL)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Vericel : to Report Fourth-Quarter 2018 Financial Results on February 26, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 08:32am EST

CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2018 financial results and business highlights.

What: Vericel Corporation Fourth-Quarter 2018 Earnings Call 
   
When: Tuesday, February 26, 2019 at 8:30am (EDT) 
   
Where: http://investors.vcel.com/events-presentations 
   
How: The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events-presentations. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. 

To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation fourth-quarter 2018 earnings call. If calling from outside the U.S., please use the international phone number (253) 237-1173.

If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events-presentations until February 26, 2020. A replay of the call will also be available until 11:15am (EDT) on March 3, 2019 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 3485006.

About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2019 Vericel Corporation. All rights reserved.

Global Media Contacts:
David Schull
Russo Partners LLC
David.schull@russopartnersllc.com 
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)

Karen Chase
Russo Partners LLC
Karen.chase@russopartnersllc.com
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)

Investor Contacts:
Chad Rubin
Solebury Trout
crubin@troutgroup.com
+1 (646) 378-2947

Lee Stern
Solebury Trout
lstern@troutgroup.com
+1 (646) 378-2922

Vericel Corporation Logo

Source: Vericel Corporation

2019 GlobeNewswire, Inc., source Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERICEL CORP
02/12VERICEL : to Report Fourth-Quarter 2018 Financial Results on February 26, 2019
AQ
01/11Vericel to Present at the 21st Annual Needham Growth Conference
GL
01/05VERICEL : Reports Publication of Outcomes Data From 954 Burn Patients Treated Wi..
AQ
01/04Vericel Reports Publication of Outcomes Data From 954 Burn Patients Treated W..
GL
2018VERICEL : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2018VERICEL CORP : Results of Operations and Financial Condition, Financial Statemen..
AQ
2018Vericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Ful..
GL
2018VERICEL : to Present at the Canaccord Genuity Medical Technologies & Diagnostic ..
AQ
2018VERICEL : to Present at the Canaccord Genuity Medical Technologies & Diagnostic ..
AQ
2018Vericel to Report Third-Quarter 2018 Financial Results on November 6, 2018
GL
More news
Financials ($)
Sales 2018 88,2 M
EBIT 2018 -7,70 M
Net income 2018 -11,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 9,58x
Capi. / Sales 2019 7,69x
Capitalization 845 M
Chart VERICEL CORP
Duration : Period :
Vericel Corp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERICEL CORP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 21,9 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Dominick C. Colangelo President, Chief Executive Officer & Director
Robert L. Zerbe Chairman
Daniel R. Orlando Chief Operating Officer
Gerard J. Michel Chief Financial & Accounting Officer
David Recker Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VERICEL CORP12.01%845
BIOGEN10.62%65 478
CSL LIMITED-0.09%59 539
ALEXION PHARMACEUTICALS32.93%28 921
BIOMARIN PHARMACEUTICAL10.38%16 736
GRIFOLS3.93%16 521